720646ca5b04dffca9ff191a8b72e741 pmc_10971921.pdf 4336c75e0f7c58e84b30d0405f72432b6d3bc88f pmc_10971921.pdf c511194529024b3b93aa26cebd00dec31426b370e9580d6d614abbca9be78c1b pmc_10971921.pdf Title: Tofacitinib and Baricitinib in Type 2 Diabetic Patients with Rheumatoid Arthritis Subject: Background and Objectives: Recently, a randomized controlled trial suggested a potential benefit of baricitinib in patients with diabetes mellitus, preserving -cell function. However, the clinical evidence currently available is limited. We aimed to assess the potential impact of tofacitinib and baricitinib on type 2 diabetes mellitus (T2DM) patients with rheumatoid arthritis. Materials and Methods: The candidates for this observational, retrospective, single-center study were selected from a cohort of 120 rheumatoid arthritis patients treated with tofacitinib or baricitinib between September 2017 and September 2023. The eligibility criteria included patients with T2DM who were receiving oral antidiabetic drugs (OADs). The primary outcome was the glycosylated hemoglobin (HbA1c) value after 6 months of a JAK inhibitor treatment. Secondary outcomes included body mass index (BMI) and rheumatoid arthritis disease activity. Differences were evaluated using Fisher’s exact test, as well as the Mann–Whitney test or the Wilcoxon test. Results: Thirteen patients were included; 46.2% (6/13) underwent treatment with tofacitinib, while 53.8% (7/13) were treated with baricitinib. At 6 months, baricitinib treatment resulted in a reduction in HbA1c (p = 0.035), with 57.1% (4/7) of patients achieving values <7%, and 28.6% (2/7) of patients requiring a reduction in OAD dosage. Concerning BMI, an increase (p = 0.022) was observed at 6 months following baricitinib administration. All the patients treated with either tofacitinib or baricitinib achieved remission or low disease activity, without requiring statistically significant changes in concomitant rheumatoid arthritis treatment. Conclusions: In T2DM patients with rheumatoid arthritis, baricitinib can improve insulin sensitivity and glucose uptake, enabling the optimization of T2DM management. Keywords: Janus kinase inhibitor; tofacitinib; baricitinib; rheumatoid arthritis; type 2 diabetes mellitus Author: Cristina Martinez-Molina, Cesar Diaz-Torne, Hye S. Park, Anna Feliu, Silvia Vidal and Hèctor Corominas Creator: LaTeX with hyperref Producer: pdfTeX-1.40.25 CreationDate: Thu Feb 22 03:50:36 2024 CET ModDate: Thu Feb 22 03:53:15 2024 CET Custom Metadata: no Metadata Stream: no Tagged: no UserProperties: no Suspects: no Form: none JavaScript: no Pages: 7 Encrypted: no Page size: 595.276 x 841.89 pts (A4) Page rot: 0 File size: 864477 bytes Optimized: no PDF version: 1.7 name type encoding emb sub uni object ID ------------------------------------ ----------------- ---------------- --- --- --- --------- WYEKQU+VnURWPalladioL-Bold Type 1 Custom yes yes yes 10 0 CQZVIY+VnURWPalladioL Type 1 Custom yes yes yes 16 0 CWCBWV+EURM10 Type 1 Builtin yes yes yes 21 0 QWDFOS+URWPalladioL-Bold Type 1 Custom yes yes yes 26 0 YVGPPL+URWPalladioL-Roma Type 1 Custom yes yes yes 32 0 LROYXY+URWPalladioL-Ital Type 1 Custom yes yes yes 37 0 HVRRJG+TimesNewRomanPS-BoldItalicMT Type 1C WinAnsi yes yes no 53 0 PDTLUH+CMSY10 Type 1 Builtin yes yes yes 70 0 QLBIEB+URWPalladioL-BoldItal Type 1 Custom yes yes yes 78 0 Jhove (Rel. 1.28.0, 2023-05-18) Date: 2024-04-26 02:40:57 CEST RepresentationInformation: pmc_10971921.pdf ReportingModule: PDF-hul, Rel. 1.12.4 (2023-03-16) LastModified: 2024-04-24 02:31:24 CEST Size: 864477 Format: PDF Version: 1.7 Status: Well-Formed and valid SignatureMatches: PDF-hul MIMEtype: application/pdf PDFMetadata: Objects: 186 FreeObjects: 1 IncrementalUpdates: 0 DocumentCatalog: PageLayout: SinglePage PageMode: UseNone Outlines: Item: Title: Introduction Destination: section.1 Item: Title: Materials and Methods Destination: section.2 Item: Title: Results Destination: section.3 Item: Title: Discussion Destination: section.4 Item: Title: Conclusions Destination: section.5 Item: Title: References Destination: section.6 Info: Title: Tofacitinib and Baricitinib in Type 2 Diabetic Patients with Rheumatoid Arthritis Author: Cristina Martinez-Molina, Cesar Diaz-Torne, Hye S. Park, Anna Feliu, Silvia Vidal and Hèctor Corominas Subject: Background and Objectives: Recently, a randomized controlled trial suggested a potential benefit of baricitinib in patients with diabetes mellitus, preserving -cell function. However, the clinical evidence currently available is limited. We aimed to assess the potential impact of tofacitinib and baricitinib on type 2 diabetes mellitus (T2DM) patients with rheumatoid arthritis. Materials and Methods: The candidates for this observational, retrospective, single-center study were selected from a cohort of 120 rheumatoid arthritis patients treated with tofacitinib or baricitinib between September 2017 and September 2023. The eligibility criteria included patients with T2DM who were receiving oral antidiabetic drugs (OADs). The primary outcome was the glycosylated hemoglobin (HbA1c) value after 6 months of a JAK inhibitor treatment. Secondary outcomes included body mass index (BMI) and rheumatoid arthritis disease activity. Differences were evaluated using Fisher’s exact test, as well as the Mann Whitney test or the Wilcoxon test. Results: Thirteen patients were included; 46.2% (6/13) underwent treatment with tofacitinib, while 53.8% (7/13) were treated with baricitinib. At 6 months, baricitinib treatment resulted in a reduction in HbA1c (p = 0.035), with 57.1% (4/7) of patients achieving values <7%, and 28.6% (2/7) of patients requiring a reduction in OAD dosage. Concerning BMI, an increase (p = 0.022) was observed at 6 months following baricitinib administration. All the patients treated with either tofacitinib or baricitinib achieved remission or low disease activity, without requiring statistically significant changes in concomitant rheumatoid arthritis treatment. Conclusions: In T2DM patients with rheumatoid arthritis, baricitinib can improve insulin sensitivity and glucose uptake, enabling the optimization of T2DM management. Keywords: Janus kinase inhibitor; tofacitinib; baricitinib; rheumatoid arthritis; type 2 diabetes mellitus Creator: LaTeX with hyperref Producer: pdfTeX-1.40.25 CreationDate: Thu Feb 22 03:50:36 CET 2024 ModDate: Thu Feb 22 03:53:15 CET 2024 ID: 0x27465c07afcc5eb083b2a023714652bf, 0x27465c07afcc5eb083b2a023714652bf Filters: FilterPipeline: FlateDecode Fonts: Type1: Font: BaseFont: CQZVIY+VnURWPalladioL FontSubset: true FirstChar: 178 LastChar: 225 FontDescriptor: FontName: CQZVIY+VnURWPalladioL Flags: Symbolic FontBBox: -166, -283, 1021, 943 FontFile: true EncodingDictionary: Differences: true ToUnicode: true Font: BaseFont: YVGPPL+URWPalladioL-Roma FontSubset: true FirstChar: 2 LastChar: 169 FontDescriptor: FontName: YVGPPL+URWPalladioL-Roma Flags: Symbolic FontBBox: -166, -283, 1021, 943 FontFile: true EncodingDictionary: Differences: true ToUnicode: true Font: BaseFont: CWCBWV+EURM10 FontSubset: true FirstChar: 12 LastChar: 20 FontDescriptor: FontName: CWCBWV+EURM10 Flags: Symbolic FontBBox: -32, -243, 1060, 720 FontFile: true ToUnicode: true Font: BaseFont: LROYXY+URWPalladioL-Ital FontSubset: true FirstChar: 46 LastChar: 118 FontDescriptor: FontName: LROYXY+URWPalladioL-Ital Flags: Symbolic FontBBox: -170, -305, 1010, 941 FontFile: true EncodingDictionary: Differences: true ToUnicode: true Font: BaseFont: PDTLUH+CMSY10 FontSubset: true FirstChar: 21 LastChar: 21 FontDescriptor: FontName: PDTLUH+CMSY10 Flags: Symbolic FontBBox: -29, -960, 1116, 775 FontFile: true ToUnicode: true Font: BaseFont: QWDFOS+URWPalladioL-Bold FontSubset: true FirstChar: 3 LastChar: 134 FontDescriptor: FontName: QWDFOS+URWPalladioL-Bold Flags: Symbolic FontBBox: -152, -301, 1000, 935 FontFile: true EncodingDictionary: Differences: true ToUnicode: true Font: BaseFont: WYEKQU+VnURWPalladioL-Bold FontSubset: true FirstChar: 177 LastChar: 177 FontDescriptor: FontName: WYEKQU+VnURWPalladioL-Bold Flags: Symbolic FontBBox: -152, -301, 1000, 935 FontFile: true EncodingDictionary: Differences: true ToUnicode: true Font: BaseFont: QLBIEB+URWPalladioL-BoldItal FontSubset: true FirstChar: 110 LastChar: 112 FontDescriptor: FontName: QLBIEB+URWPalladioL-BoldItal Flags: Symbolic FontBBox: -170, -300, 1073, 935 FontFile: true EncodingDictionary: Differences: true ToUnicode: true Pages: Page: Sequence: 1 Annotations: Annotation: Subtype: Link Rect: 107, 293, 152, 302 Annotation: Subtype: Link Rect: 34, 281, 146, 290 Annotation: Subtype: Link Rect: 34, 164, 96, 186 Annotation: Subtype: Link Rect: 125, 90, 154, 99 Annotation: Subtype: Link Rect: 34, 78, 149, 87 Annotation: Subtype: Link Rect: 34, 756, 178, 792 Annotation: Subtype: Link Rect: 515, 756, 560, 792 Annotation: Subtype: Link Rect: 165, 662, 176, 676 Annotation: Subtype: Link Rect: 271, 662, 282, 676 Annotation: Subtype: Link Rect: 352, 662, 363, 676 Annotation: Subtype: Link Rect: 423, 662, 435, 676 Annotation: Subtype: Link Rect: 512, 662, 523, 676 Annotation: Subtype: Link Rect: 164, 652, 175, 663 Annotation: Subtype: Link Rect: 390, 170, 397, 178 ActionDest: 92 Annotation: Subtype: Link Rect: 318, 157, 325, 166 ActionDest: 92 Annotation: Subtype: Link Rect: 237, 119, 244, 128 ActionDest: 92 Annotation: Subtype: Link Rect: 478, 119, 485, 128 ActionDest: 92 Annotation: Subtype: Link Rect: 323, 94, 330, 103 ActionDest: 92 Annotation: Subtype: Link Rect: 333, 94, 340, 103 ActionDest: 95 Annotation: Subtype: Link Rect: 333, 69, 340, 78 ActionDest: 92 Annotation: Subtype: Link Rect: 340, 69, 347, 78 ActionDest: 95 Annotation: Subtype: Link Rect: 115, 17, 272, 28 Annotation: Subtype: Link Rect: 404, 17, 560, 28 Annotation: Subtype: Link Rect: 34, 366, 87, 385 Page: Sequence: 2 Annotations: Annotation: Subtype: Link Rect: 230, 731, 237, 740 ActionDest: 92 Annotation: Subtype: Link Rect: 238, 731, 245, 740 ActionDest: 95 Annotation: Subtype: Link Rect: 436, 718, 443, 727 ActionDest: 95 Annotation: Subtype: Link Rect: 426, 693, 433, 702 ActionDest: 95 Annotation: Subtype: Link Rect: 433, 693, 440, 702 ActionDest: 95 Annotation: Subtype: Link Rect: 496, 655, 503, 665 ActionDest: 95 Annotation: Subtype: Link Rect: 503, 655, 510, 665 ActionDest: 95 Annotation: Subtype: Link Rect: 472, 517, 484, 526 ActionDest: 95 Annotation: Subtype: Link Rect: 237, 241, 249, 250 ActionDest: 95 Annotation: Subtype: Link Rect: 278, 87, 285, 99 ActionDest: 75 Page: Sequence: 3 Annotations: Annotation: Subtype: Link Rect: 252, 213, 258, 225 ActionDest: 83 Annotation: Subtype: Link Rect: 278, 213, 285, 225 ActionDest: 83 Annotation: Subtype: Link Rect: 500, 176, 507, 188 ActionDest: 86 Page: Sequence: 4 Page: Sequence: 5 Annotations: Annotation: Subtype: Link Rect: 204, 298, 216, 307 ActionDest: 95 Annotation: Subtype: Link Rect: 483, 285, 490, 294 ActionDest: 95 Annotation: Subtype: Link Rect: 204, 222, 211, 231 ActionDest: 95 Annotation: Subtype: Link Rect: 211, 222, 218, 231 ActionDest: 95 Annotation: Subtype: Link Rect: 407, 147, 419, 156 ActionDest: 95 Annotation: Subtype: Link Rect: 502, 109, 514, 118 ActionDest: 95 Annotation: Subtype: Link Rect: 447, 71, 454, 81 ActionDest: 92 Annotation: Subtype: Link Rect: 455, 71, 461, 81 ActionDest: 95 Page: Sequence: 6 Annotations: Annotation: Subtype: Link Rect: 336, 744, 343, 752 ActionDest: 92 Annotation: Subtype: Link Rect: 496, 744, 503, 752 ActionDest: 92 Annotation: Subtype: Link Rect: 467, 731, 474, 740 ActionDest: 92 Annotation: Subtype: Link Rect: 416, 668, 428, 677 ActionDest: 95 Annotation: Subtype: Link Rect: 401, 580, 408, 589 ActionDest: 92 Annotation: Subtype: Link Rect: 109, 160, 146, 170 Annotation: Subtype: Link Rect: 152, 160, 188, 170 Annotation: Subtype: Link Rect: 443, 125, 481, 136 Annotation: Subtype: Link Rect: 487, 125, 523, 136 Annotation: Subtype: Link Rect: 59, 103, 96, 113 Annotation: Subtype: Link Rect: 102, 103, 138, 113 Annotation: Subtype: Link Rect: 519, 79, 557, 90 Annotation: Subtype: Link Rect: 59, 68, 95, 78 Page: Sequence: 7 Annotations: Annotation: Subtype: Link Rect: 200, 730, 237, 741 Annotation: Subtype: Link Rect: 243, 730, 279, 741 Annotation: Subtype: Link Rect: 104, 696, 142, 706 Annotation: Subtype: Link Rect: 148, 696, 184, 706 Annotation: Subtype: Link Rect: 144, 673, 182, 683 Annotation: Subtype: Link Rect: 188, 673, 224, 683 Annotation: Subtype: Link Rect: 455, 660, 560, 671 Annotation: Subtype: Link Rect: 56, 649, 389, 660 Annotation: Subtype: Link Rect: 455, 637, 560, 648 Annotation: Subtype: Link Rect: 56, 626, 398, 637 Annotation: Subtype: Link Rect: 390, 591, 427, 602 Annotation: Subtype: Link Rect: 434, 591, 470, 602 Annotation: Subtype: Link Rect: 255, 558, 292, 568 Annotation: Subtype: Link Rect: 298, 558, 334, 568 Annotation: Subtype: Link Rect: 293, 522, 331, 533 Annotation: Subtype: Link Rect: 337, 522, 373, 533 Annotation: Subtype: Link Rect: 104, 489, 142, 499 Annotation: Subtype: Link Rect: 148, 489, 184, 499 Annotation: Subtype: Link Rect: 419, 465, 456, 476 Annotation: Subtype: Link Rect: 462, 465, 498, 476 Annotation: Subtype: Link Rect: 113, 431, 150, 441 Annotation: Subtype: Link Rect: 157, 431, 193, 441 Checksum: 6560e693 Type: CRC32 Checksum: 720646ca5b04dffca9ff191a8b72e741 Type: MD5 Checksum: 4336c75e0f7c58e84b30d0405f72432b6d3bc88f Type: SHA-1 Checksum: c511194529024b3b93aa26cebd00dec31426b370e9580d6d614abbca9be78c1b Type: SHA-256